%0 Journal Article
%A Placke, Jan-Malte
%A Rajcsanyi, Luisa Sophie
%A Herbst, Rudolf
%A Terheyden, Patrick
%A Utikal, Jochen
%A Pföhler, Claudia
%A Kreuter, Alexander
%A Mohr, Peter
%A Gutzmer, Ralf
%A Weichenthal, Michael
%A Meier, Friedegund
%A Berking, Carola
%A Leiter, Ulrike
%A Seier, Johanna
%A Krefting, Frederik
%A Tasdogan, Alpaslan
%A Lodde, Georg C
%A Livingstone, Elisabeth
%A Zimmer, Lisa
%A Roesch, Alexander
%A Griewank, Klaus
%A Schadendorf, Dirk
%A Ugurel, Selma
%T Presence of brain metastasis differentially impacts long-term survival after first-line therapy in melanoma depending on BRAF mutation status.
%J Frontiers in immunology
%V 16
%@ 1664-3224
%C Lausanne
%I Frontiers Media
%M DKFZ-2025-00478
%P 1536642
%D 2025
%X Modern therapeutic strategies have significantly improved the prognosis of advanced melanoma patients. Predictive factors of therapy response include serum LDH; however, predictive markers for long-term survival are currently largely lacking.Patients diagnosed with stage IV melanoma (AJCCv8) of cutaneous origin or unknown primary were identified from the prospective multicenter German Dermatologic Cooperative Oncology Group (DeCOG) skin cancer registry ADOREG. Baseline characteristics were compared between patient groups with short-term versus long-term survival. Statistical analysis included ROC analysis and multinomial regression analysis.Of 3066 stage IV melanoma patients entered into the ADOREG between 05/2014 and 06/2021, 395 were identified for this study, of whom 301 (76.2
%K Humans
%K Proto-Oncogene Proteins B-raf: genetics
%K Melanoma: genetics
%K Melanoma: mortality
%K Melanoma: drug therapy
%K Male
%K Brain Neoplasms: secondary
%K Brain Neoplasms: genetics
%K Brain Neoplasms: mortality
%K Female
%K Middle Aged
%K Aged
%K Mutation
%K Adult
%K Skin Neoplasms: genetics
%K Skin Neoplasms: mortality
%K Skin Neoplasms: drug therapy
%K Skin Neoplasms: pathology
%K Prognosis
%K Neoplasm Staging
%K Aged, 80 and over
%K Prospective Studies
%K Immune Checkpoint Inhibitors: therapeutic use
%K Biomarkers, Tumor: genetics
%K Registries
%K BRAF (Other)
%K brain metastases (Other)
%K immune checkpoint inhibitor (ICI) (Other)
%K long-term survival (Other)
%K melanoma (Other)
%K targeted therapy (Other)
%K Proto-Oncogene Proteins B-raf (NLM Chemicals)
%K BRAF protein, human (NLM Chemicals)
%K Immune Checkpoint Inhibitors (NLM Chemicals)
%K Biomarkers, Tumor (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40028330
%2 pmc:PMC11868123
%R 10.3389/fimmu.2025.1536642
%U https://inrepo02.dkfz.de/record/299520